- Published on
Pathology - Osteomalacia.
I. Definition & Epidemiology:
I. Definition & Epidemiology:
- Definition: Osteomalacia is a metabolic bone disease. Crucially, it's characterized by inadequate mineralization of osteoid, resulting in soft, weakened bones. This means the bone matrix (osteoid) doesn't harden properly.
- Epidemiology: Relatively rare in developed nations. Predominantly affects the elderly population.
- Primary Cause: Almost all cases stem from vitamin D deficiency. Understanding the why behind the deficiency is critical.
- Causes of Vitamin D Deficiency:
- Insufficient sun exposure: Lack of UV-B radiation needed for vitamin D synthesis in the skin.
- Malabsorption: Conditions affecting nutrient absorption from the gut (e.g., celiac disease, Crohn's disease).
- Chronic liver disease: Impaired vitamin D metabolism.
- Chronic kidney disease: Reduced ability to activate vitamin D in the kidneys.
- Bone Matrix Mineralization Failure: Insufficient mineralization of the bone matrix (osteoid) leads to a buildup of unmineralized osteoid. This is the hallmark of the disease.
- Structural Weakness: The excess unmineralized osteoid weakens bone structure, resulting in increased risk of deformity and fractures. Think of it like unbaked cookie dough versus a properly baked cookie – the dough lacks structural integrity.
- Diffuse Bone Pain and Tenderness: This is a common presenting complaint, but it's important to remember that it's non-specific. Many other conditions cause bone pain.
- Proximal Muscle Weakness: Weakness in the muscles of the shoulders and hips is another key symptom.
- Undiagnosed Cases: A significant number of cases likely go undetected due to the nonspecific nature of symptoms, emphasizing the need for thorough investigation when appropriate.
- Excessive Unmineralized Osteoid: Microscopic examination reveals bony trabeculae (bone struts) covered by a significantly thicker-than-normal layer of unmineralized osteoid. This is the definitive histopathological finding confirming the diagnosis.
- Treatment & Prognosis: Vitamin D supplementation typically leads to rapid bone mineralization and symptom resolution. However, some bone deformities may persist.
- Osteoid: The unmineralized organic matrix of bone. It's the "building material" that should harden with calcium and phosphate.
- Non-specific Symptoms: Osteomalacia's symptoms are not unique to the disease, making diagnosis challenging.
- Vitamin D's Crucial Role: Vitamin D is essential for calcium absorption and bone mineralization.
- Published on
Pathology – Benign Bone Tumors
I. Osteochondroma
I. Osteochondroma
- Definition: Benign bone-forming tumour.
- Location: Solitary exophytic nodule arising from the metaphysis of long bones near the epiphyseal growth plate.
- Population: Common in children.
- Histology:
- Outer fibrous perichondrium.
- Cartilage cap.
- Underlying bony stalk.
- Key takeaway: Think "bone spur" growing outwards from the growth plate of a long bone in a child.
- Definition: Benign cartilage-forming tumour.
- Location: Two main types:
- Enchondromas: Medulla of bones (hands and feet are common).
- Periosteal chondromas: Surface of bone (proximal humerus is characteristic).
- Presentation: Often discovered incidentally (no symptoms).
- Histology: Chondrocytes within an abundant cartilaginous matrix.
- Key takeaway: Cartilage-based tumour, location distinguishes the subtypes.
- Definition: Benign bone-forming tumour.
- Location: Long bones of children/young adults (proximal femur is common).
- Presentation: Characteristic nocturnal pain.
- Radiographic Appearance: Small lucent nidus (<1cm) on plain radiographs.< />pan>
- Histology: Well-circumscribed, hypervascular area of bony trabeculae surrounded by reactive bone.
- Key takeaway: Small, painful lesion easily visualized on X-ray; pain is a key clinical feature.
- Definition: Benign, but locally aggressive neoplasm.
- Location: Ends of long bones.
- Population: Young adults (20-45 years).
- Presentation: Pain and swelling at the tumour site.
- Histology: Sheets of neoplastic ovoid mononuclear cells with interspersed large osteoclast-like giant cells.
- Prognosis: ~25% local recurrence rate after excision. Distant metastasis is rare.
- Key takeaway: Although benign, its local aggressiveness and potential for recurrence are significant.
- Published on
Pathology - -Septic Arthritis
I. Definition:
I. Definition:
- Infection within a joint. This is the core concept – remember this first.
- Any age: Septic arthritis can affect anyone.
- Increased Risk: Individuals with pre-existing joint conditions are significantly more vulnerable. Think of this as a weakened defense system making the joint more susceptible.
- Hematogenous Spread (Most Common): The infection travels through the bloodstream to the joint. This is the primary pathway.
- Penetrating Trauma (Less Common): Infection can be introduced directly into the joint via injury (e.g., a puncture wound).
- Staphylococcus aureus (S. aureus): This bacterium is the primary culprit in almost all cases. Memorize this.
- Phagocyte Limitation: The joint space has limited access for phagocytes (immune cells that engulf and destroy pathogens). This makes it difficult for the body to fight the infection naturally. This is a key factor in why the infection spreads so rapidly.
- Rapid Destruction: Septic arthritis progresses swiftly, causing irreversible joint damage if antibiotics aren't administered promptly. Early intervention is critical.
- Classic Signs of Inflammation: The affected joint is intensely painful, hot, red, and swollen. This is a hallmark of septic arthritis; remember these four key characteristics (pain, heat, redness, swelling).
- Microscopy: Joint fluid analysis reveals neutrophils (a type of white blood cell indicating infection) but no crystals (ruling out gout or pseudogout).
- Culture: Essential for identifying the specific bacteria (usually S. aureus) and determining its antibiotic susceptibility. Culturing both joint fluid and blood is crucial for accurate diagnosis and treatment.
- Irreversible Joint Damage: Without appropriate antibiotic treatment, permanent joint destruction is inevitable. This highlights the urgency of prompt diagnosis and treatment.
- S. aureus is the most common cause.
- Early antibiotic treatment is crucial to prevent irreversible joint damage.
- The four cardinal signs of inflammation (pain, heat, redness, swelling) are present.
- Joint fluid analysis is essential for diagnosis and guiding treatment.
- Published on
- Published on
- Published on
Pathology - Crystal Arthropathies
I. Definition & Pathogenesis
A. Gout
Microscopic examination of joint fluid is crucial for differentiating gout and pseudogout:
I. Definition & Pathogenesis
- Crystal Arthropathies: A family of joint diseases stemming from crystal deposition within the joints.
- Pathogenic Mechanism: Crystals trigger an inflammatory response. Neutrophils attempt to phagocytose (engulf) the crystals, leading to degranulation and the release of damaging enzymes. This enzymatic action causes joint damage.
A. Gout
- Etiology: Deposition of urate crystals in joints. Primarily caused by hyperuricemia (high uric acid levels in the blood), often due to impaired renal (kidney) excretion of urate.
- Acute Gout: Presents as an acutely painful, swollen, and red joint. While any joint can be affected, the first metatarsophalangeal joint (base of the big toe) is highly characteristic.
- Chronic Tophaceous Gout: In individuals with persistently high urate levels, large urate deposits (tophi) can form in the skin and around joints.
- Etiology: Deposition of calcium pyrophosphate crystals in joints. Pyrophosphate is a byproduct of nucleotide triphosphate hydrolysis within cartilage chondrocytes.
- Pathogenesis: Shedding of these crystals into the joint space initiates an acute arthritis closely resembling gout.
- Clinical Presentation: Typically affects older women, commonly involving the knee and wrist joints.
Microscopic examination of joint fluid is crucial for differentiating gout and pseudogout:
- Joint Fluid: Contains neutrophils and crystals.
- Urate Crystals (Gout): Needle-shaped; exhibit negative birefringence under polarized light.
- Pyrophosphate Crystals (Pseudogout): Rhomboid or rod-shaped; exhibit positive birefringence under polarized light. The difference in birefringence is key for distinguishing between the two conditions.
- Published on
Pathology - Spondyloarthropathies
I. Definition & Epidemiology:
A. Ankylosing Spondylitis:
I. Definition & Epidemiology:
- Definition: Spondyloarthropathies are inflammatory joint diseases affecting the spine and peripheral joints, characterized by arthritis and enthesitis (inflammation at tendon/ligament-bone insertion sites).
- Epidemiology: These are common diseases (affecting ~1% of the population), predominantly affecting young adults (20-40 years old) with a slight male bias.
- HLA-B27 Association: A strong genetic association exists with the HLA-B27 allele. This is a crucial risk factor.
- Older Theories: Initially, researchers hypothesized that an unidentified "arthritogenic peptide" presented by HLA-B27 to CD8+ T cells triggered inflammation.
- Current Understanding: Recent focus is on HLA-B27 protein itself. The HLA-B27 heavy chain is prone to misfolding, forming abnormal homodimers. Studies (e.g., in transgenic rats) show that this misfolding leads to endoplasmic reticulum stress and IL-23 production via the T-helper 17 pathway, driving inflammation.
A. Ankylosing Spondylitis:
- Prevalence: Affects approximately 0.5% of the population, typically presenting in young adults (20-40 years).
- Presentation: Lower back pain due to sacroiliitis (inflammation of the sacroiliac joints) is the hallmark symptom.
- Extra-articular Manifestations: Inflammation can extend beyond the joints, affecting structures like the eyes (iritis), lungs (pulmonary fibrosis), and aorta (aortitis).
- Onset: Develops within one month of an infection elsewhere in the body.
- Infections: Commonly associated with genitourinary infections (e.g., Chlamydia) or gastrointestinal infections (e.g., Shigella, Salmonella, Campylobacter).
- Mechanism: Possibly due to bacterial antigens or DNA deposition in joints, although this isn't definitively proven.
- Presentation: Pain and stiffness in the lower back, knees, ankles, and feet; enthesitis is frequent.
- Prevalence: Occurs in approximately 5% of patients with psoriasis.
- Joint Involvement: Primarily affects distal interphalangeal joints (joints at the tips of the fingers and toes), potentially causing significant deformity.
- Cause: Currently unknown.
- Prevalence: Found in about 10% of individuals with inflammatory bowel disease.
- Joint Involvement: Typically affects sacroiliac and lower limb joints asymmetrically.
- Cause: Unknown.
- Published on
Pathology - Chronic myelogenous leukemia
A myeloproliferative neoplasm mostly affecting the granulocytic lineage, consistently related with the BCR-ABL1 fusion gene on the Philadelphia chromosome.
Epidemiology • Incidence ranges from 1 to 2 per 100,000 individuals annually. • The peak age of onset is between 50 and 70 years old.
Aetiology: Unknown. Genetics • Chronic myelogenous leukaemia (CML) is typically characterized by the t(9;22) translocation, which produces the Philadelphia chromosome. • This translocation fuses the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9. • The resulting BCR-ABL1 protein exhibits increased tyrosine kinase activity, resulting in the persistent activation of signal transduction pathways and uncontrolled proliferation of myeloid cells.
Presentation • The majority of patients receive a diagnosis during the chronic phase of the disease, characterized by an elevated white cell count. • Hepatosplenomegaly frequently accompanies the diagnosis.
Peripheral blood • Leukocytosis resulting from elevated neutrophil counts at various maturation phases. • Basophilia and eosinophilia are prevalent. No dysplasia is observed.
Bone marrow • Bone marrow trephines exhibit hypercellularity attributed to elevated quantities of neutrophils and their precursors. • Megakaryocytes are generally diminutive and hypolobated. • Blasts constitute less than 5% of marrow cells throughout the chronic phase.
Prognosis • The outcome has significantly improved following the introduction of the tyrosine kinase inhibitor, imatinib, resulting in 5-year survival rates of 80–90%. • Disease progression is typically indicated by an elevation in circulating blasts to over 10% (accelerated phase) and culminates in acute leukemia when blasts constitute more than 20% of circulating cells.
A myeloproliferative neoplasm mostly affecting the granulocytic lineage, consistently related with the BCR-ABL1 fusion gene on the Philadelphia chromosome.
Epidemiology • Incidence ranges from 1 to 2 per 100,000 individuals annually. • The peak age of onset is between 50 and 70 years old.
Aetiology: Unknown. Genetics • Chronic myelogenous leukaemia (CML) is typically characterized by the t(9;22) translocation, which produces the Philadelphia chromosome. • This translocation fuses the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9. • The resulting BCR-ABL1 protein exhibits increased tyrosine kinase activity, resulting in the persistent activation of signal transduction pathways and uncontrolled proliferation of myeloid cells.
Presentation • The majority of patients receive a diagnosis during the chronic phase of the disease, characterized by an elevated white cell count. • Hepatosplenomegaly frequently accompanies the diagnosis.
Peripheral blood • Leukocytosis resulting from elevated neutrophil counts at various maturation phases. • Basophilia and eosinophilia are prevalent. No dysplasia is observed.
Bone marrow • Bone marrow trephines exhibit hypercellularity attributed to elevated quantities of neutrophils and their precursors. • Megakaryocytes are generally diminutive and hypolobated. • Blasts constitute less than 5% of marrow cells throughout the chronic phase.
Prognosis • The outcome has significantly improved following the introduction of the tyrosine kinase inhibitor, imatinib, resulting in 5-year survival rates of 80–90%. • Disease progression is typically indicated by an elevation in circulating blasts to over 10% (accelerated phase) and culminates in acute leukemia when blasts constitute more than 20% of circulating cells.
- Published on
Pathology - Acute B-lymphoblastic leukemia
Definition: A hematological neoplasm consisting of malignant B-lymphoid blasts.
Epidemiology: Rare occurrence. • Predominantly a pediatric ailment (75% of cases occur in those under 6 years of age)
Aetiology • Predominantly unknown, although there is an indication of a hereditary component in certain instances. Pathogenesis: Mutations in a hematopoietic stem cell result in the clonal proliferation of immature B-lymphoid blasts. • Lymphoid blasts proliferate rapidly, overwhelming normal bone marrow, entering peripheral circulation, and infiltrating other organs.
Presentation: • Abrupt development of bone marrow failure characterized by severe anemia and thrombocytopenia. The leukocyte count may be diminished, normal, or elevated. Infiltration of other organs is prevalent, resulting in lymphadenopathy, hepatosplenomegaly, bone pain, headache, vomiting, and cranial nerve palsies.
Microscopy • By definition, more than 20% of cells in the peripheral blood or bone marrow are lymphoid blasts. Lymphoid blasts are medium to large cells characterized by a high nuclear-to-cytoplasmic ratio. The immunophenotype of B-lymphoid blasts often includes the expression of CD19, CD79a, CD10, Pax5, and TdT.
Prognosis: Contemporary treatment protocols exhibit remarkable success rates, with complete remission attained in over 95% of pediatric patients.
- Published on
Pathology - Polycythemia vera
A myeloproliferative neoplasm primarily affecting the erythroid lineage, typically linked to a somatic gain-of-function mutation in the JAK2 gene. Epidemiology: Incidence ranges from 1 to 2.5 cases per 100,000 individuals annually. The median age upon diagnosis is 60 years. • There is a minor masculine predominance.
Aetiology: Unknown. Genetics: Over 95% of cases exhibit the JAK2 V617F mutation, resulting in uncontrolled proliferation of all myeloid cells, particularly affecting the erythroid lineage. The advancement of the disease correlates with the development of chromosomal abnormalities.
Presentation • May be incidentally detected with a full blood count or manifest with symptoms associated with hyperviscosity (headache, dizziness, visual disturbances, venous or arterial thrombosis). • The majority of individuals exhibit plethoric conditions and hepatosplenomegaly. Complete blood count: elevated hemoglobin, increased red cell count, heightened hematocrit (HCT), and augmented packed cell volume (PCV). • Frequently, I monitor white blood cell count and platelet levels. The bone marrow exhibits hypercellularity resulting from an elevation in all myeloid lineages, termed 'panmyelosis.' Erythroid progenitors and megakaryocytes are the most prominent cell types. Megakaryocytes exhibit loose clustering and frequently demonstrate considerable variation in size and morphology.
Prognosis: Median survival exceeds 10 years with treatment. The majority of patients succumb to thrombosis or hemorrhage. Approximately 20% succumb to the progression of myelodysplasia or acute myeloid leukemia (AML).
A myeloproliferative neoplasm primarily affecting the erythroid lineage, typically linked to a somatic gain-of-function mutation in the JAK2 gene. Epidemiology: Incidence ranges from 1 to 2.5 cases per 100,000 individuals annually. The median age upon diagnosis is 60 years. • There is a minor masculine predominance.
Aetiology: Unknown. Genetics: Over 95% of cases exhibit the JAK2 V617F mutation, resulting in uncontrolled proliferation of all myeloid cells, particularly affecting the erythroid lineage. The advancement of the disease correlates with the development of chromosomal abnormalities.
Presentation • May be incidentally detected with a full blood count or manifest with symptoms associated with hyperviscosity (headache, dizziness, visual disturbances, venous or arterial thrombosis). • The majority of individuals exhibit plethoric conditions and hepatosplenomegaly. Complete blood count: elevated hemoglobin, increased red cell count, heightened hematocrit (HCT), and augmented packed cell volume (PCV). • Frequently, I monitor white blood cell count and platelet levels. The bone marrow exhibits hypercellularity resulting from an elevation in all myeloid lineages, termed 'panmyelosis.' Erythroid progenitors and megakaryocytes are the most prominent cell types. Megakaryocytes exhibit loose clustering and frequently demonstrate considerable variation in size and morphology.
Prognosis: Median survival exceeds 10 years with treatment. The majority of patients succumb to thrombosis or hemorrhage. Approximately 20% succumb to the progression of myelodysplasia or acute myeloid leukemia (AML).
